Evaxion A/S（EVAX）股票分析

$3.070

+0.093 (+3.02%)收盘时

Loading chart…

High: 3.191
Open: 3.000
VWAP: 3.08
Vol: 60.66K
Mkt Cap: 15.53M
Low: 2.990
Amount: 187.05K
EV/EBITDA, TTM: -3.74

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

evaxion.ai

AI analysis of Evaxion A/S (EVAX)

hold

Currently, Evaxion Biotech A/S (EVAX) is not a strong buy due to its low current price of $3.01, which is significantly below the analyst price targets of $9 and $10. The stock's RSI of 30.46 indicates it is oversold, but the recent 5-day change of -9.06% raises concerns about momentum. The main risk is the company's net loss of $3.7 million in Q2 2026, which highlights ongoing cash burn and financial instability.

估值指标

The current forward P/E ratio for Evaxion A/S (EVAX) is 3.57, compared to its 5-year average forward P/E of -3.67.

Forward P/E

Overvalued

5Y Average P/E

-3.67

Current P/E

3.57

高估

2.29

低估

-9.64

Forward EV/EBITDA

Undervalued

5Y Average EV/EBITDA

-1.48

Current EV/EBITDA

-3.74

高估

-0.21

低估

-2.75

Forward P/S

Fair

5Y Average P/S

11.60

Current P/S

5.32

高估

28.12

低估

-4.93

Alphio AI Price Scenarios for EVAX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%EVAX

$3.29

情景价格

Base

Base · 50%EVAX

$3.03

情景价格

Bear

Bear · 25%EVAX

$2.68

情景价格

事件时间线

2026-07-17 (ET)